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Abstract
Objective: To determine the relationship between serum S100A8/A9 and S100A12 and the 
maintenance of clinical inactive disease (CID) in patients with polyarticular forms of juvenile 
idiopathic arthritis (PF-JIA) while on anti-tumor necrosis factor therapy (anti-TNF) and disease 
flare following withdrawal of anti-TNF.
Methods: In this prospective, multicenter study, 137 patients with PF-JIA were enrolled while in 
CID on anti-TNF. Patients were observed for the initial 6 months. Those who maintained CID had 
anti-TNF withdrawn and were followed for 8 months to assess for flare. Serum S100 levels were 
measured at baseline and when anti-TNF was withdrawn. Rank correlation, Mann-Whitney test, 
Kruskal-Wallis test, receiver-operating-characteristic (ROC) curve and Kaplan-Meier survival 
analysis were used to assess the relationship between S100 levels and maintenance of CID and 
disease flare.
Results: Twenty-four out of 130 (18%) evaluable patients lost CID while on anti-TNF, and 39 of 
106 (37%) evaluable patients flared following anti-TNF withdrawal. S100A8/A9 and S100A12 
levels were elevated in up to 45% of patients. In the ROC analysis, S100 levels did not predict 
maintenance of CID and disease flare. Elevated S100A8/A9 levels did not predict disease flare 
within 30, 60, 90 days or 8 months following anti-TNF withdrawal, and S100A12 had modest 
predictive ability for flare within 30, 60, and 90 days. S100A12 levels at time of withdrawal and 
time to disease flare was inversely correlated (r=−0.36).
Conclusion: Serum S100 levels did not predict maintenance of CID or disease flare, with 
S100A12 levels only moderately correlating inversely with time to disease flare.
Most children with polyarticular forms of juvenile idiopathic arthritis (PF-JIA), i.e. extended 
oligoarthritis and polyarthritis, achieve clinical inactive disease (CID) while on 
contemporary treatment (1, 2). Anti-tumor necrosis factor (TNF) therapy has markedly 
improved the ability to achieve CID and favorable long-term outcomes in patients with PF-
JIA (3–7). Therefore, anti-TNF therapy is used in up to 60% of patients with PF-JIA (2, 8). 
Still, anti-TNF therapy has potential side effects, is costly, and patients often desire 
discontinuation of therapy if possible (9, 10). It is well known that some patients can 
maintain CID after discontinuation of anti-TNF therapy, hence achieve clinical remission off 
therapy (1). A large proportion of patients, however, will experience a disease flare or lose 
the CID state after discontinuation of anti-rheumatic therapy, possibly even more so after 
discontinuation of anti-TNF therapy (11). So far, specific prognostic factors to identify 
patients who may safely discontinue anti-TNF therapy without subsequent disease flare have 
been elusive.
The S100A8/A9 complex (also known as myeloid-related peptide [MRP] 8/14 or 
calprotectin) and the S100A12 protein, are members of the calgranulin family and released 
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from inflammatory cells of the myeloid lineage (12). It has been speculated that elevated 
serum levels of the S100A8/A9 and S100A12 may be indicators of a state of subclinical 
inflammation. Subclinical inflammation is considered to be undetectable on clinical 
examination or by measuring conventional inflammatory markers, for example, C-reactive 
protein (CRP) or erythrocyte sedimentation rate (13, 14). Furthermore, subclinical 
inflammation maybe present in patients with PF-JIA in CID while on treatment. Subclinical 
inflammation is likely a risk factor for recurrence of clinically overt signs and symptoms of 
JIA once anti-rheumatic therapy is decreased or stopped (15). In line with this hypothesis 
there is initial evidence that elevated serum S100 levels while on therapy, at the time of 
withdrawal, indicate an increased risk for loss of CID after treatment withdrawal (16, 17). In 
another study, comparing the biomarkers S100A8/A9, S100A12 and high-sensitivity CRP, 
S100A12 was the single most accurate biomarker in predicting loss of CID within 6 months 
after discontinuation of methotrexate (MTX) (18).
The clinical characteristics of this multicenter study cohort and clinical factors relating to the 
maintenance of CID while on treatment and the occurrence of disease flare after anti-TNF 
withdrawal have been identified and reported separately (19).
The objectives of this prospective study were to determine the performance of the serum 
biomarker S100A8/A9 and S100A12 at baseline and their relation to maintenance of CID, 
and their level at the time of anti-TNF therapy withdrawal and their relation to disease flare 
in patients with PF-JIA.
PATIENTS AND METHODS
Study design:
Details of the study design have been reported elsewhere (19). One hundred thirty-seven 
patients with PF-JIA, i.e. extended oligoarthritis, rheumatoid factor (RF) positive 
polyarthritis and RF negative polyarthritis while on anti-TNF treatment and in CID were 
enrolled in 16 tertiary pediatric centers in the US. The study consisted of two phases. First, 
there was an initial 6-month phase during which anti-TNF therapy was continued and which 
consisted of quarterly monitoring to assess maintenance of CID. This was followed by anti-
TNF withdrawal and a second phase during which patients were observed monthly over 8 
months for disease flare, the primary outcome of the study. Patients were only allowed to 
enter the second phase of the study if CID was maintained during the first phase of the study.
Definitions:
CID was defined according to the American College of Rheumatology provisional criteria 
(20). Disease flare was defined according to the stringent preliminary flare criteria (21).
Inclusion and exclusion criteria:
The detailed inclusion and exclusion criteria are reported elsewhere (22). In brief, patients 
with PF-JIA were between 4 and 20 years of age, were in a state of CID while receiving 
anti-TNF therapy (adalimumab [ADA], etanercept [ETN], or infliximab [IFX]) and all food 
and drug administration label exclusions had to be absent. Patients were excluded if they 
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were diagnosed with other acute or chronic inflammatory illnesses, were previously treated 
with rituximab, received concurrent treatment with another biologic agent or more than low-
dose corticosteroids (prednisone-equivalent of greater than 0.2 mg/kg/day, or greater than 10 
mg/day).
Anti-TNF therapy:
Allowable anti-TNF therapy included ADA, ETN and IFX. Patients could receive therapy 
with nonsteroidal anti-inflammatory drugs (NSAIDs), MTX or other non-biological disease-
modifying anti-rheumatic drugs (DMARDs), and low-dose corticosteroid (prednisone-
equivalent up to 0.2 mg/kg/days); those treatments were to remain unchanged during the 
study.
Serum samples and S100 protein measurement:
S100 proteins were measured twice during the course of the study, at baseline, i.e. at the 
beginning of the first phase, and at the time of anti-TNF withdrawal. Serum was separated 
within two hours of blood sampling. Serum samples were immediately frozen and stored at 
−80°C. The serum samples were subsequently shipped frozen. Concentrations of 
S100A8/A9 and S100A12 were determined by a double sandwich ELISA system established 
in our laboratory, as previously described (23, 24). All samples were diluted to the linear 
range of the assay. The readers of the laboratory assays were blinded to the disease course. 
For comparison with earlier studies, internal control sera were included in all ELISA studies.
Statistical analysis:
Microsoft Excel (Redmond, WA, USA) and GraphPad Prism 6 (La Jolla, CA, USA) were 
used for data analysis. Since the S100 levels were not normally distributed, summary 
measures were reported as medians (range). Rank correlation analyses between different 
parameters were performed in order to obtain the Spearman correlation coefficient. Between 
and among group comparisons of the serum S100 levels were done by the Mann-Whitney U 
test (in case of two groups) and the Kruskal-Wallis test (in case of more than two groups), 
respectively. Receiver operating characteristic (ROC) curve analysis was used to assess the 
predictive accuracy of serum S100 levels in regards to maintenance of CID (phase 1) and 
occurrence of disease flare (phase 2). For the ROC curve analysis the area-under-the-curve 
(AUC) and 95% confidence interval was calculated (25). Optimal threshold levels for 
S100A8/A9 and S100A12 were identified by the levels that resulted in the highest likelihood 
ratio (sensitivity/[1-specificity]). If optimal levels could not be identified this way, 
previously identified threshold levels were applied (18). The Youden index (sensitivity + 
specificity −1) was calculated (range −1 to +1), where +1 represents a perfect test and zero 
represents a non-discriminatory test. Furthermore, Kaplan-Meier analysis was performed to 
estimate flare-free survival in patients with lower vs. elevated serum S100 levels. 
Distributions were compared via chi square test. Discrepancy between S100A8/A9 and 
S100A12 was defined by the presence of an above-threshold S100A8/A9 and a below-
threshold S100A12 level or vice versa.
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RESULTS
Patient characteristics and overall distribution of serum S100 levels:
Clinical characteristics are shown in Table 1. Of the initially 137 patients enrolled, 7 patients 
dropped out (6 due to loss of follow-up or non-compliance and 1 due to a change in 
diagnosis to psoriatic arthritis), resulting in 130 evaluable patients. Serum S100A8/A9 and 
S100A12 levels at the baseline visit were not significantly different among the 3 different 
categories of PF-JIA, between patients taking or not taking MTX nor between the different 
anti-TNF agents.
Correlation of serum S100 levels
There was only a moderate correlation between S100 protein levels at the baseline visit and 
the end of the first phase, i.e. immediately prior to discontinuation of TNF blockade even 
though patients were in CID at both time points (for S100A8/A9: Spearman correlation 
coefficient of r = 0.36; for S100A12: r = 0.45). There was a very strong correlation between 
S100A8/A9 and S100A12, taking into account measurements both at baseline and at the end 
of the first phase (r = 0.82) (Figure 1). There was at most a weak inverse correlation between 
baseline S100A8/A9 levels and age (r=−0.19), weight (r=−0.17), and duration of CID (r=
−0.22) and no correlation with disease duration. There was no significant association 
between baseline serum S100A12 levels and age, weight, disease duration and duration of 
CID, respectively.
Serum S100 levels and maintenance of clinical inactive disease on anti-TNF therapy
Comparison of S100A8/A9 and S100A12 levels between patients who maintained CID 
(n=106) and those who did not did (n=24) not reveal significant differences when taking into 
account the different JIA categories, the specific anti-TNF agent or accompanying MTX 
therapy (Table 2 and Supplementary Figure 1). ROC curve analysis suggested that neither 
serum S100A8/A9 nor S100A12 level at baseline predicted maintenance of CID throughout 
the 6 months of the first phase (for S100A8/A9: AUC 0.52, 95% confidence interval [CI] 
0.38–0.65; for S100A12: AUC 0.53, CI 0.38–0.67) (Figure 2A and Figure 2C).
Serum S100 levels and disease flare after anti-TNF withdrawal
Comparison of S100A8/A9 and S100A12 levels between patients who flared (n=39) and 
those who did not flare (n=67) did not reveal significant differences when taking into 
account the different JIA categories, the specific anti-TNF agent or accompanying MTX 
therapy (Table 2 and Supplementary Figure 1). ROC curve analysis of the serum S100 level 
at the time of anti-TNF withdrawal and its relation to disease flare or no flare during the 
eight months of the second phase indicated that neither serum S100A8/A9 nor S100A12 
levels predicted disease flare (Figure 2B and Figure 2D). ROC analysis of the serum 
S100A12 levels and its relation to flare within 30, 60 and 90 days after anti-TNF withdrawal 
indicated an AUC (95% CI) of 0.64 (0.50–0.77), 0.66 (0.54–0.79) and 0.64 (0.51–0.77), 
indicating, at best, poor prediction of disease flare (Table 3). The same analysis for 
S100A8A9 did not yield significant results (AUC [95% CI] 0.51 [0.31–0.70], 0.51 [0.33–
0.69] and 0.51 [0.34–0.67], respectively). An ideal threshold level for the prediction of flare 
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could not be determined for S100A8/A9 for any time frame since the ROC curve was very 
close to the line of no-discrimination. For S100A12, the optimal threshold level for 
prediction of flare at 30, 60, and 90 days was 120 ng/ml (positive likelihood ratio between 
1.94 and 1.86).
Based on an established threshold level for serum S100A8/A9 of 690 ng/ml for the 
prediction of flare after MTX withdrawal with the same assay (18), a large proportion of 
patients had elevated S100A8/A9 levels at baseline (59 of 130 patients [45.4%]) and at the 
time of anti-TNF withdrawal (43 of 106 patients [40.6%]). Based on a threshold level for 
serum S100A12 of 120 ng/ml which is both the upper limit of normal in healthy controls in 
our laboratory (mean plus two standard deviations) and the optimal threshold level based on 
the ROC analysis (see above), the level was elevated at baseline in 46 of 130 patients 
[35.4%] and at the time of anti-TNF withdrawal in 35 of 106 patients [33.0%]. MTX 
background therapy did not affect the distribution of patients with elevated levels, except for 
the S100A8/A9 levels at the time of anti-TNF withdrawal (elevated in 24 of 41 [58.5%] of 
patients on MTX compared to 19 of 65 [29.2%] not on MTX; chi square test, p<0.01).
Kaplan-Meier survival analysis comparing disease flare within 8 months, 90 days, 60 days 
and 30 days after anti-TNF withdrawal did not demonstrate significant differences between 
patients with elevated vs. normal S100 protein levels (Figure 3).
There was no correlation between time to disease flare and S100A8/A9 levels at time of 
anti-TNF withdrawal (Spearman rank coefficient r=−0.16, p=0.35), and moderate inverse 
correlation for S100A12 (r=−0.36; p=0.04) (Supplementary Table 2).
Discrepancies between serum S100A8/A9 and S100A12 levels
Since there was at least some difference in the prognostic accuracy between S100A8/A9 and 
S100A12 levels, we investigated discrepant values. Among the 39 patients who developed a 
disease flare following anti-TNF withdrawal, 4 patients (10.3%) had discrepant values (2 
had an elevated S100A8/A9 and a normal S100A12, and 2 had a normal S100A8/A9 and an 
elevated S100A12). Among the 67 patients without disease flare following anti-TNF 
withdrawal, 13 patients (19.4%) had discrepant values (11 had an elevated S100A8/A9 and a 
normal S100A12, and two had a normal S100A8/A9 and an elevated S100A12).
DISCUSSION
In this prospective study of patients with PF-JIA and CID, serum S100 levels obtained while 
on anti-TNF therapy predicted neither maintenance of CID nor the occurrence of flare 
during an 8-month anti-TNF withdrawal period.
These findings are in contrast with previously published data. In another large-scale, 
prospective treatment withdrawal study of 364 patients with JIA in CID on MTX therapy, 
S100A8/A9 levels were measured in 188 patients and elevated S100A8/A9 levels, identified 
by post hoc analysis, were predictive of disease flare within 12 months of observation 
(hazard ratio 2.24, 95% CI 1.39–3.62) (17). Samples from the same study were re-analyzed 
to demonstrate that S100A12 had an even better predictive value in that cohort (hazard ratio 
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2.81, 95% CI 1.70–4.65) (18). In a retrospective, exploratory analysis of samples of patients 
with JIA in CID on ETN therapy within 2 separate registries, elevated S100A8A9 levels, 
again identified by post hoc analysis, at the time of ETN withdrawal indicated an increased 
risk of disease flare within six months (positive likelihood ratio 3.5, ROC 0.75 with 95% CI 
0.55–0.95) (16). In these studies, findings were derived post hoc, subjecting them to bias 
from de facto multiple hypothesis testing which may in part account for the divergence in 
cut-off values across studies. Currently, these is a trial prospectively studying antirheumatic 
drug withdrawal based on biomarker levels (ISRCTN69963079).
Several aspects need to be considered, including substantial differences between those 
previous studies and this study, and factors affecting sensitivity, specificity or both. For 
example, the primary outcome in another study was loss of CID (rather than disease flare by 
the more stringent flare criteria used in this study), and sampling of S100 protein levels was 
incomplete in that study (17, 18). Furthermore, a retrospective study on anti-TNF 
withdrawal reported a much higher rate of disease flare (54% in an 8-month period) but this 
was a small study and, thus, selection bias may have occurred (16). An additional difference 
between our study and previous studies is that previous studies addressed patients who had 
all anti-rheumatic drugs withdrawn, whereas in our study only the anti-TNF therapy was 
discontinued. Of note, concomitant MTX therapy did not affect flare rate or S100 protein 
levels in this study.
Sensitivity of the biomarkers may be affected by several issues. The disease in patients with 
PF-JIA in CID on anti-TNF therapy may be intrinsically more unstable than PF-JIA in CID 
on MTX therapy. This may also be indicated by others’ findings on a high risk of disease 
relapse after discontinuation of anti-TNF therapy vs. discontinuation of MTX therapy (11). 
In fact, it appears that serum S100A12 levels were perhaps slightly better at predicting flare 
within 30, 60 or 90 days of anti-TNF withdrawal than over the entire 8 months of the second 
phase in this study; however, this effect was not seen for S100A8/A9. However, the study is 
underpowered to determine whether elevated serum S100A12 levels may predict a higher 
risk of flare within this time frame (due to the rare number of events). Furthermore, S100 
protein kinetics may play a role. While the precise elimination half-life of S100A12 is 
unknown, it is presumably rather short (in the order of hours rather than days), similar to the 
half-life of the related S100A8/A9 proteins (26, 27). In addition, TNF is a known stimulus 
for S100A8/A9 and S100A12 secretion by inflammatory cells and anti-TNF therapy down-
regulates S100 protein expression (27, 28). Anti-TNF agents are typically applied in 
intervals that range from 1 week (ETN), to 2 weeks (ADA) and to 8 weeks (IFX), and the 
half-lives range from 3 days (for the fusion molecule ETN) to 10–20 days (for the 
monoclonal antibodies ADA and IFX) (29–31). Furthermore, mathematic modeling 
indicates that free TNF-alpha levels drop rapidly (within hours) following administration of 
anti-TNF agents (32). Therefore, the timing of serum sampling in regards to anti-TNF 
application may be critical when assessing serum S100 protein levels. We are unable to 
account for this factor since the dates of the anti-TNF administration were not recorded 
during this study.
Finally, the specificity of the biomarkers may be limited as well. Other conditions, especially 
infections, may affect serum S100 protein levels substantially, even in minor infections 
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which occur frequently in children (33–35). The source of elevated serum S100 protein 
levels therefore is difficult to determine individually and may be prone to misinterpretation, 
issues that are difficult to overcome.
Slight differences in diagnostic accuracy between S100A8/A9 levels and S100A12 levels 
may exist because S100A8/A9 is predominantly produced by monocytes whereas S100A12 
is mainly produced by neutrophils (36). One may speculate that TNF differentially affects 
monocytes and neutrophils (37), thus affecting the pattern of S100 protein secretion during 
anti-TNF therapy, more so than during MTX therapy (which may target lymphocytes more 
prominently), for example (38).
Furthermore, we cannot exclude that technical issues may contribute to the marked 
variability and lack of predictive value. For this study, we have used an in-house ELISA 
using polyclonal S100A8/A9 and S100A12 antibodies. In the meantime, we have developed 
a more robust assay using monoclonal S100A12 antibody which is being used for current 
studies (unpublished data). Of note, several (including commercial) assays exist both for 
S100A8/A9 and for S100A12; while each of these assays may deliver consistent results, 
absolute reported values differ substantially (39). Therefore, caution should be applied when 
interpreting S100A8/A9 or S100A12 levels.
It may be speculated that further studies on the concept of subclinical arthritis and its 
relation to maintenance of CID and disease flare should account for these issues and 
incorporate, for example, standardized sampling conditions (as it relates to anti-TNF 
dosing), excluding sampling at the time of obvious infection, and incorporate further 
measures, such as imaging studies to assess for evidence of joint-related subclinical 
inflammation, e.g. joint ultrasound (40, 41). In the long-term, the goal will be to guide 
clinicians’ decisions on when or when not to withdraw anti-rheumatic therapies in individual 
patients. The utility of a biomarker-supported withdrawal strategy is currently being tested in 
a prospective clinical trial (ISRCTN69963079) (18). Furthermore, more studies are needed 
to identify potential novel biomarkers of subclinical active disease.
In summary, analysis of the serum biomarkers S100A8/A9 and S100A12 in a prospective 
cohort study of patients with PF-JIA who were closely monitored in CID and had anti-TNF 
therapy withdrawn, indicated that S100 protein levels did not predict maintenance of CID or 
the occurrence of disease flare over an 8-month period following the withdrawal. Further 
studies on the concept of subclinical inflammation in JIA should possibly include more 
stringent handling of the biomarker sampling and possibly also include imaging studies.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1: 
Correlation between individual subject’s S100A8/A9 and S100A12 levels both at baseline 
and at the end of the first phase (Spearman correlation coefficient 0.82).
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Figure 2: 
Receiver operating curve (ROC) curve characteristics of serum S100 levels: (A) S100A8/A9 
at baseline and the occurrence of loss of clinically inactive disease during six months of anti-
TNF continuation (area-under the curve [AUC] 0.52, 95% confidence interval [CI] 0.38–
0.65), (B) S100A8/A9 at the time of anti-TNF agent withdrawal and the occurrence of 
disease flare within eight months following anti-TNF withdrawal (AUC 0.56, CI 0.44–0.67), 
(C)) S100A12 at baseline and the occurrence of loss of clinically inactive disease during six 
months of anti-TNF continuation (AUC 0.53, CI 0.38–0.67), (B) S100A12 at the time of 
anti-TNF agent withdrawal and the occurrence of disease flare within eight months 
following anti-TNF withdrawal (AUC 0.51, CI 0.39–0.62).
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Figure 3: 
Kaplan-Meier survival analysis comparing flare-free survival throughout the eight-month 
phase following anti-TNF withdrawal according to elevated vs. normal (A) serum 
S100A8/A9 and (B) serum S100A12 levels at the time of anti-TNF withdrawal (Hazard ratio 
per logrank test for S100A8/A9 >690 ng/ml 0.72 (95% CI 0.36–1.42) and for S100A12 
>120 ng/ml 1.13 [95% CI 0.55–2.33])
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Table 1:
Patient characteristics at the baseline study visit
Characteristic Evaluable cohort (n=130)
Age – mean (standard deviation) 11.2 (4.5) years
Sex – n (%) 97 (74.6%) female
Category – n (%)
 Extended oligoarthritis 18 (13.8%)
 Seronegative polyarthritis 97 (74.6%)
 Seropositive polyarthritis 15 (11.5%)
On methotrexate therapy 54 (41.5%)
Type of anti-TNF therapy – n (%)
 Adalimumab 20 (15.4%)
 Etanercept 104 (80.0%)
 Infliximab 6 (4.6%)
Disease duration – mean (standard deviation) 5.0 (3.6) years
Duration of CID – mean (standard deviation) 1.2 (1.8) years
Baseline S100 protein level – median (range) S100A8/A9 [ng/ml] S100A12 [ng/ml]
 All patients 652 (49–3892) 93 (0–1558)
 According to category
  Extended oligoarthritis 817 (158–2070) 91 (0–890)
  Seronegative polyarthritis 610 (49–3892) 93 (11–1558)
  Seropositive polyarthritis 820 (200–1890) 114 (16–566)
 According to MTX therapy
  On MTX therapy 718 (94–3000) 84 (11–1558)
  Not on MTX therapy 617 (49–3892) 95 (0–1029)
 According to anti-TNF agent
  Adalimumab 875 (133–2180) 115 (14–479)
  Etanercept 595 (49–3892) 90 (0–1558)
  Infliximab 900 (180–2070) 121 (21–890)
anti-TNF, anti-tumor necrosis factor; CID, clinically inactive disease; MTX, methotrexate
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